[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658251":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":34,"studyPopulation":34,"armGroups":44,"interventions":57,"overallOfficials":65,"centralContacts":34,"locations":34,"responsibleParty":70,"collaborators":34,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":34,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":34,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":34,"overallStatus":93,"whyStopped":34,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":34},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":34},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of Participants Who Experience an Adverse Event (AE)","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention","Up to approximately 43 days",{"measure":14,"description":11,"timeFrame":15},"Number of Participants Who Discontinue Study Due to an AE","Up to approximately 28 days",[17,21,25,28,31],{"measure":18,"description":19,"timeFrame":20},"Plasma Concentration at 24 Hours (C24) of MK-8644","Blood samples will be collected at designated timepoints to determine the C24 of MK-8644","At designated timepoints up to 24 hours post-dose",{"measure":22,"description":23,"timeFrame":24},"Maximum Plasma Concentration (Cmax) of MK-8644","Blood samples will be collected at designated timepoints to determine the Cmax of MK-8644","Predose and at designated timepoints up to 4 days post-dose",{"measure":26,"description":27,"timeFrame":24},"Time to Maximum Plasma Concentration (Tmax) of MK-8644","Blood samples will be collected at designated timepoints to determine the Tmax of MK-8644",{"measure":29,"description":30,"timeFrame":24},"Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-8644","Blood samples will be collected at designated timepoints to determine the AUC0-Last of MK-8644",{"measure":32,"description":33,"timeFrame":24},"Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-8644","Blood samples will be collected at designated timepoints to determine the AUC0-Inf of MK-8644",null,{"allocation":36,"interventionModel":37,"interventionModelDescription":34,"primaryPurpose":38,"observationalModel":34,"timePerspective":34,"maskingInfo":39},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":40,"maskingDescription":34,"whoMasked":41},"DOUBLE",[42,43],"PARTICIPANT","INVESTIGATOR",[45,51],{"label":46,"type":47,"description":48,"interventionNames":49},"MK-8644","EXPERIMENTAL","Participants receive MK-8644 orally under fasted or fed conditions depending on randomization.",[50],"Drug: MK-8644",{"label":52,"type":53,"description":54,"interventionNames":55},"Placebo","PLACEBO_COMPARATOR","Participants receive matching placebo for MK-8644 orally under fasted or fed conditions depending on randomization.",[56],"Drug: Placebo for MK-8644",[58,62],{"type":59,"name":46,"description":60,"armGroupLabels":61,"otherNames":34},"DRUG","Oral administration",[46],{"type":59,"name":63,"description":60,"armGroupLabels":64,"otherNames":34},"Placebo for MK-8644",[52],[66],{"name":67,"affiliation":68,"role":69},"Medical Director","Merck Sharpe & Dohme LLC","STUDY_DIRECTOR",{"type":71,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100658251","phase-1-a-clinical-trial-of-mk-8644-in-healthy-participants-and-participants-with-psoriasis-mk-8644-001-100658251",false,"NCT07850310","A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)","A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses, Food Effect, and Relative Bioavailability of MK-8644 in Healthy Japanese and Non-Japanese Participants and Multiple Doses of MK-8644 in Patients With Mild to Moderate Plaque Psoriasis","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is in good health\n* Has a BMI between 18 and 36 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.\n* Has a history of cancer.\n* Has a history of significant multiple and\u002For severe allergies.\n* Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, tuberculosis, or HIV.",true,"ALL","18 Years","65 Years",{"count":84,"type":85},132,"ESTIMATED","INTERVENTIONAL",[88],"PHASE1","The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.\n\nThis trial will help researchers learn about the safety of MK-8644 and if participants tolerate it. Tolerate means participants will receive MK-8644 in the trial unless they need to stop it due to health problems.",[91,92],"Psoriasis","Healthy","NOT_YET_RECRUITING","2026-09-24",{"date":96,"type":97},"2026-09-30","ACTUAL",{"date":99,"type":85},"2026-10-06",{"date":101,"type":85},"2027-12-13",{"name":5,"class":6}]